SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending as investors digest Warren Buffett's transition away from daily operations and the firm's massive cash position. Community members are debating the company's future under incoming CEO Greg Abel, the strategic implications of its substantial liquidity, and its role as a stable anchor in a volatile market.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased community interest and discussion regarding its potential for post-quantum cryptographic security and institutional integration. Supporters are highlighting accumulation efforts during recent price consolidation, while active debate continues between long-term believers and those skeptical of the project's recent market performance.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is currently generating significant community buzz as investors debate its long-term potential compared to other memecoins, specifically highlighting its brand IP and retail presence. Discussions are heavily focused on the coin's technical price levels, with many holders actively accumulating during volatility in hopes of a broader breakout alongside the wider crypto market.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing intense community debate following the rollout of the Goliath mainnet, with active users weighing its potential as institutional financial infrastructure against frustration over stagnant price action and past project communication. While some investors are utilizing the staking rewards to accumulate holdings, others are expressing significant skepticism, citing concerns about censorship and the transparency of the leadership team.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is in the spotlight as investors digest recent positive phase III clinical data for its kidney disease drug, povetacicept, while actively debating the long-term growth trajectory of its broader pipeline beyond its cystic fibrosis franchise. The community is focused on the potential for accelerated FDA approval pathways following this clinical milestone, alongside ongoing discussions about the strategic value of the company's expanding non-opioid pain management and rare disease programs.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is at a critical juncture as investors await an impending FDA decision following a positive 10-3 advisory committee vote that suggested the clinical data is evaluable despite ongoing skepticism. Community sentiment is deeply polarized, with active discussions focusing on high short interest, the potential for significant dilution through an authorized share increase, and whether the FDA will prioritize unmet medical need or stand by its previous regulatory critiques.

Workday, Inc. engages in the development of enterprise cloud applications for finance and human resources. The firm delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. It operates through the Cloud Applications segment. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending as investors grapple with significant stock price volatility and a broader debate about the impact of agentic AI on enterprise software business models. The community remains deeply divided, with some highlighting the company's valuation as a compelling entry point while others express concerns over decelerating growth and aggressive competition from emerging AI solutions.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart Holdings is trending as investors weigh the potential of a conditional bank charter against continued volatility in credit markets. The community remains deeply divided, with many expressing frustration over the stock's price action while others point to fundamental growth metrics and the possibility of a short squeeze as key catalysts to watch.

Alight, Inc. engages in the provision of cloud-based integrated digital human capital and business solutions. The company was founded on June 01, 2017 and is headquartered in Chicago, IL.

Alight Inc. - Ordinary Shares - Class A

Alight Inc. 

Alight is currently driving significant community discussion following a period of extreme volatility and a reverse stock split, as investors debate whether the company is a deep-value turnaround opportunity or a high-risk trap. While some point to recurring revenue and KKR's recent carve-out deal as catalysts for long-term upside, others express skepticism due to ongoing dilution concerns, debt levels, and the company's long-term downward trajectory.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

Dave Inc

Dave Inc. is trending as investors weigh strong earnings growth and aggressive share buybacks against broader market volatility and concerns over delinquency rates. The community remains divided between long-term bulls highlighting the company's AI-driven underwriting advantages and skeptical bears focusing on macro headwinds and sector-wide fintech pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia Quaratino, EVP Chief Medical Officer of Innate Pharma, will participate in the panel...

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end and...

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company PR Newswire SAN FRANCISCO, June 2, 2026 Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)SAN FRANCISCO, June 2...

Outcome of Innate Pharmas 2026 Annual General Meeting

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) announced the voting results of its shareholders at the Annual General Meeting (AGM), which took place on May 21, 2026, in Marseille. All resolutions were voted. A total of 94 votes were cast out of a...

Innate Pharma to participate in the Jefferies Global Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced...

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its business update and consolidated financial results for the quarter ending March 31...

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

Regulatory News: Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) releases its...

Innate Pharma (IPHA) Expected to Announce Quarterly Earnings on Wednesday

Innate Pharma (NASDAQ:IPHA) will be releasing its Q1 2026 TU earnings before the market opens on Wednesday, May 13. (View Earnings Report at...

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT, to provide an update on business progress for the first quarter of 2026...

Innate Pharma (NASDAQ:IPHA) Shares Down 0.7% - Here's What Happened

Innate Pharma (NASDAQ:IPHA) Stock Price Down 0.7% - Here's Why...

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma - ADR

IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

IPHAInnate Pharma

Fundamentals

Connect Stocktwits to ChatGPT

Latest IPHA News